Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis
<b>Background:</b> Even though many metabolic liver diseases can now be diagnosed using blood tests and diagnostic imaging, early diagnosis remains difficult. Understanding mechanisms contributing to the progression from Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Alcohol...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/78 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589006075854848 |
|---|---|
| author | Yuta Hirata Yasunaru Sakuma Hideo Ogiso Ryozo Nagai Kenichi Aizawa |
| author_facet | Yuta Hirata Yasunaru Sakuma Hideo Ogiso Ryozo Nagai Kenichi Aizawa |
| author_sort | Yuta Hirata |
| collection | DOAJ |
| description | <b>Background:</b> Even though many metabolic liver diseases can now be diagnosed using blood tests and diagnostic imaging, early diagnosis remains difficult. Understanding mechanisms contributing to the progression from Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Alcoholic Hepatitis (AH) to cirrhosis is critical to reduce the burden of end-stage liver disease. Monitoring individual bile acids has been proposed as a way to distinguish various liver disorders. <b>Methods:</b> This study explored bile acid profiles in patients with MASH and AH. Plasma samples from patients with MASH, AH, and a control group were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify bile acid concentrations. Targeted metabolomic analysis was performed to compare bile acid levels between the hepatitis and control groups. <b>Results:</b> Concentrations of ursodeoxycholic acid (UDCA), chenodeoxycholic acid (CDCA), taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA), taurochenodeoxycholic acid (TCDCA), glycoursodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), and glycocholic acid (GCA) were significantly elevated in the hepatitis group. Correlation analysis revealed strong positive relationships between the total and direct bilirubin levels and TUDCA and GCDCA. Aspartate aminotransferase (AST) showed strong positive correlations with TCDCA and GCDCA. Child–Pugh score, Fibrosis-4 index, and non-alcoholic fatty liver disease fibrosis score were positively correlated with GCA, whereas the aspartate aminotransferase-to-platelet ratio correlated with TCA, TCDCA, and GCA. The model for end-stage liver disease (MELD) score showed a strong positive correlation with GCDCA. <b>Implications:</b> GCDCA may serve as a predictive biomarker for liver damage, potentially enabling early diagnosis and targeted intervention in patients with MASH and AH. |
| format | Article |
| id | doaj-art-be4c2be181774f109fb9a23df1d48857 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-be4c2be181774f109fb9a23df1d488572025-01-24T13:23:56ZengMDPI AGBiomedicines2227-90592024-12-011317810.3390/biomedicines13010078Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic HepatitisYuta Hirata0Yasunaru Sakuma1Hideo Ogiso2Ryozo Nagai3Kenichi Aizawa4Division of Gastroenterological, Department of Surgery, General and Transplant Surgery, Jichi Medical University, Shimotsuke 329-0498, Tochigi, JapanDivision of Gastroenterological, Department of Surgery, General and Transplant Surgery, Jichi Medical University, Shimotsuke 329-0498, Tochigi, JapanDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, Tochigi, JapanJichi Medical University, Shimotsuke 329-0498, Tochigi, JapanDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan<b>Background:</b> Even though many metabolic liver diseases can now be diagnosed using blood tests and diagnostic imaging, early diagnosis remains difficult. Understanding mechanisms contributing to the progression from Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Alcoholic Hepatitis (AH) to cirrhosis is critical to reduce the burden of end-stage liver disease. Monitoring individual bile acids has been proposed as a way to distinguish various liver disorders. <b>Methods:</b> This study explored bile acid profiles in patients with MASH and AH. Plasma samples from patients with MASH, AH, and a control group were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify bile acid concentrations. Targeted metabolomic analysis was performed to compare bile acid levels between the hepatitis and control groups. <b>Results:</b> Concentrations of ursodeoxycholic acid (UDCA), chenodeoxycholic acid (CDCA), taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA), taurochenodeoxycholic acid (TCDCA), glycoursodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), and glycocholic acid (GCA) were significantly elevated in the hepatitis group. Correlation analysis revealed strong positive relationships between the total and direct bilirubin levels and TUDCA and GCDCA. Aspartate aminotransferase (AST) showed strong positive correlations with TCDCA and GCDCA. Child–Pugh score, Fibrosis-4 index, and non-alcoholic fatty liver disease fibrosis score were positively correlated with GCA, whereas the aspartate aminotransferase-to-platelet ratio correlated with TCA, TCDCA, and GCA. The model for end-stage liver disease (MELD) score showed a strong positive correlation with GCDCA. <b>Implications:</b> GCDCA may serve as a predictive biomarker for liver damage, potentially enabling early diagnosis and targeted intervention in patients with MASH and AH.https://www.mdpi.com/2227-9059/13/1/78metabolic dysfunction-associated steatohepatitisalcoholic hepatitisbile acidsliver cirrhosisbiomarkersmass spectrometry |
| spellingShingle | Yuta Hirata Yasunaru Sakuma Hideo Ogiso Ryozo Nagai Kenichi Aizawa Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis Biomedicines metabolic dysfunction-associated steatohepatitis alcoholic hepatitis bile acids liver cirrhosis biomarkers mass spectrometry |
| title | Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis |
| title_full | Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis |
| title_fullStr | Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis |
| title_full_unstemmed | Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis |
| title_short | Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis |
| title_sort | targeted plasma bile acid metabolomic analysis in metabolic dysfunction associated steatohepatitis and alcoholic hepatitis |
| topic | metabolic dysfunction-associated steatohepatitis alcoholic hepatitis bile acids liver cirrhosis biomarkers mass spectrometry |
| url | https://www.mdpi.com/2227-9059/13/1/78 |
| work_keys_str_mv | AT yutahirata targetedplasmabileacidmetabolomicanalysisinmetabolicdysfunctionassociatedsteatohepatitisandalcoholichepatitis AT yasunarusakuma targetedplasmabileacidmetabolomicanalysisinmetabolicdysfunctionassociatedsteatohepatitisandalcoholichepatitis AT hideoogiso targetedplasmabileacidmetabolomicanalysisinmetabolicdysfunctionassociatedsteatohepatitisandalcoholichepatitis AT ryozonagai targetedplasmabileacidmetabolomicanalysisinmetabolicdysfunctionassociatedsteatohepatitisandalcoholichepatitis AT kenichiaizawa targetedplasmabileacidmetabolomicanalysisinmetabolicdysfunctionassociatedsteatohepatitisandalcoholichepatitis |